Skip to main content
. 2016 Aug 18;11(8):e0161470. doi: 10.1371/journal.pone.0161470

Fig 5. ABCB1 mRNA levels increase initially in imatinib and dasatinib resistant cell lines but decrease following emergence of additional resistance mechanisms.

Fig 5

Expression levels of ABCB1 mRNA were assessed in (a) K562, (b) KU812 and (c, d) K562-Dox cells resistant to (a, b) imatinib or (c, d) dasatinib. Expression levels were then correlated with other, previously defined, resistance mechanisms denoted by red and blue lines[15]. Specifically, (a) LYN mRNA expression, % of (b) imatinib resistant (F359C) and (c) dasatinib resistant (V299L) kinase domain mutations, (d) BCR-ABL1 mRNA expression. ABCB1 mRNA expression represents the mean of at least four independent experiments performed in triplicate. Statistical analyses compared mRNA levels (as a percentage of house keeping genes) in each resistant intermediate to corresponding control cells. Analyses were performed using unpaired Student’s t-test (Welch’s correction was applied for data groups with unequal SD) or Mann-Whitney Rank Sum test. Statistically significant p-values are denoted by carets (^) or asterisks (* p<0.05; ** p<0.01). Error bars represent SEM. IM = imatinib; DAS = dasatinib.